文献速递妇科产科

激素治疗与局部晚期宫颈癌放化疗后长期结局的关联

Association of hormone therapy with long-term outcomes after chemoradiation for locally advanced cervical cancer.
PubMed 文献 · Am J Obstet Gynecol · 2026-07-17

本研究基于TriNetX多国电子健康记录网络开展回顾性多机构队列研究,纳入<45岁、FIGO 2018 IIB-IVA期、接受一线同步放化疗的宫颈癌患者,采用1年landmark分析及倾向评分匹配。匹配后4656例(激素治疗组2328例、非激素治疗组2328例),中位随访约11年。激素治疗与2型糖尿病、脑血管事件、压缩性骨折风险降低及总生存改善相关,未增加血栓栓塞及乳腺癌、结直肠癌风险。

要点

  • 同步放化疗后1年内启动雌激素类激素治疗与2型糖尿病、脑血管事件及压缩性骨折风险降低相关。
  • 激素治疗组总生存显著改善,且未增加血栓栓塞、乳腺癌或结直肠癌的发生风险。
  • 对早绝经的局部晚期宫颈癌年轻患者,激素治疗可能兼具安全性及全身健康获益。

核心结论

  • 在局部晚期宫颈癌同步放化疗后的年轻患者中,1年内启动激素治疗与代谢、骨骼及脑血管疾病负担降低和总生存改善相关,长期随访未增加肿瘤学风险。

研究设计与样本

  • 回顾性多机构队列研究,使用TriNetX多国电子健康记录网络,纳入<45岁、FIGO 2018 IIB-IVA期、接受一线同步放化疗的宫颈癌患者。
  • 采用以放化疗启动后整1年为索引事件的landmark分析以消除永生时间偏倚,暴露组为1年内启动雌激素类激素治疗者。
  • 排除1年landmark前死亡或发生主要结局者,采用倾向评分匹配(基于绝对标准化均数差)平衡协变量。

主要发现

  • 匹配后共4656例(激素治疗组2328例,非激素治疗组2328例);激素治疗组中位随访11.8年(四分位距7.3-17.2),非激素治疗组11.0年(四分位距6.6-16.4)。
  • 血栓栓塞、乳腺癌、结直肠癌发生率无显著差异;激素治疗与总生存显著改善相关(HR 0.81,95%CI 0.63-0.91)。
  • 初始归类为非激素治疗使用者中,2328例里有112例(4.8%)在1年索引事件后有激素治疗暴露记录。

关键数值与推荐

  • 主要结局包括新发2型糖尿病、脑血管疾病、骨质疏松、压缩性骨折、血栓栓塞、乳腺癌和结直肠癌;次要结局为总生存,采用风险比评估。
  • 倾向评分匹配模型纳入索引事件时年龄、当前年龄、种族、体质指数、Charlson合并症指数评分及转移部位(腹主动脉旁淋巴结、盆腔淋巴结、膀胱、结直肠)。

临床怎么用

  • 对接受同步放化疗后早绝经的局部晚期宫颈癌年轻患者,可考虑在治疗开始后1年内启动雌激素类激素治疗以改善代谢、骨骼及脑血管长期结局。
  • 激素治疗未显示增加血栓栓塞及乳腺癌、结直肠癌风险,支持在该治疗不足人群中开展个体化激素治疗决策。

局限性

  • 为回顾性队列研究,可能存在残余混杂。
  • 聚合平台无法可靠量化激素治疗的累积疗程及随访期间停药情况。
  • 初始非激素治疗组中有4.8%在1年索引事件后出现激素治疗暴露记录,可能造成暴露错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent chemoradiotherapy for locally advanced cervical cancer frequently induces premature menopause in young patients, resulting in long-term metabolic, skeletal, and cardiovascular morbidity. Despite guideline recommendations, hormone therapy remains underutilized because of persistent concerns regarding its safety and potential effects on oncologic outcomes. OBJECTIVE: To evaluate the association of hormone therapy with long-term metabolic, skeletal, cardiovascular, oncologic, and survival outcomes in young patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. STUDY DESIGN: This was a retrospective, multiinstitutional cohort study using a large multinational electronic health record network (TriNetX). The study included women aged<45 years with newly diagnosed International Federation of Gynecology and Obstetrics 2018 stage IIB-IVA cervical cancer who underwent first-line concurrent chemoradiotherapy. To eliminate immortal time bias, we performed a landmark analysis with the index event defined as exactly 1 year following the initiation of chemoradiotherapy. The exposure group included patients who initiated estrogen-based hormone therapy within this 1-year window. Patients who died or developed primary outcomes before the 1-year landmark were excluded. Propensity score matching was performed using absolute standardized mean differences to balance covariates. The matching model included age at the index event, current age, race, body mass index, Charlson Comorbidity Index score, and metastatic sites (para-aortic lymph node, pelvic lymph node, bladder, and colorectal). The primary outcomes included incident type 2 diabetes mellitus, cerebrovascular disease, osteoporosis, compression fracture, thromboembolism, breast cancer, and colorectal cancer. The secondary outcomes included overall survival. Outcomes were assessed using hazard ratios. RESULTS: After propensity score matching, 4656 patients were included (2328 receiving hormone therapy and 2328 not receiving hormone therapy). The median follow-up time was 11.8 years (interquartile range, 7.3 to 17.2) for the hormone therapy group and 11.0 years (interquartile range, 6.6-16.4) for the nonhormone therapy group. Among patients initially classified as nonhormone therapy users, 112 of 2328 (4.8%) subsequently had recorded hormone therapy exposure after the 1-year index event. Cumulative hormone therapy duration and discontinuation during follow-up were not reliably quantifiable in the aggregate platform. Compared with nonhormone therapy users, hormone therapy use was associated with a significantly lower risk of type 2 diabetes mellitus (5.3% vs 9.8%; hazard ratios, 0.59; 95% confidence interval, 0.32-0.81), cerebrovascular events (5.1% vs 8.9%; hazard ratios, .71; 95% confidence interval, 0.39-0.91), and compression fractures (3.1% vs 7.4%; hazard ratios, 0.69; 95% confidence interval, 0.33-0.93). There were no significant differences in incidences of thromboembolism, breast cancer, or colorectal cancer. The use of hormone therapy was also associated with significantly improved overall survival (hormone therapy, 0.81; 95% confidence interval, 0.63-0.91). CONCLUSION: In this large multinational cohort of young patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy, initiating hormone therapy within the first year was associated with reduced metabolic, skeletal, and cerebrovascular morbidity and improved overall survival, without an increased risk of oncologic outcomes during long-term follow-up. These findings support the safety and potential systemic health benefits of hormone therapy in this undertreated population.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lu TF, Shih YH, Chen YF, et al. Association of hormone therapy with long-term outcomes after chemoradiation for locally advanced cervical cancer. Am J Obstet Gynecol. 2026. PMID: 42468866. doi:10.1016/j.ajog.2026.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。